Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

118.30 -0.18 (-0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
46 47 Next >
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
3 Biotech Stocks to Sell in October
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29
Reuters 
Via Benzinga
Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences... 
Via Benzinga
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
 
Via Benzinga
Why Is Gilead Sciences (GILD) Stock Up Today?
Gilead Sciences has a low valuation, but no growth. Perhaps settling a patent lawsuit will help give GILD stock the boost it needs. 
Via InvestorPlace
Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
 
Via Benzinga
7 Monthly Dividend Stocks to Buy for Safety
These safe monthly dividend stocks offer investors incredible dividend yields and healthy upside potential 
Via InvestorPlace
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.63% on an annualized basis producing an average annual return of 7.98%. Currently, Gilead Sciences has a market... 
Via Benzinga
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
 
Via Benzinga
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease.  Since the first reports of monkeypox infection in the United States started popping up in... 
Via Benzinga
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
 
Via Benzinga
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
 
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says
Gilead Sciences Inc (NASDAQ: GILD) disclosed agreements with generic manufacturers that delay the U.S. launch of generic TAF products from 2025 to 2031/2032.  
Via Benzinga
Taking Charge of Your Care This Blood Cancer Awareness Month
(BPT) - Being empowered often comes from being informed. And when it comes to diseases like blood cancer, having or not having information can make a significant difference in outcomes. 
Via Brandpoint
Topics Death
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
 
Via Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
Why HIV Testing Should Be an Important and Normal Part of Your Self-Care Routine
(BPT) - The COVID-19 pandemic introduced unprecedented challenges and altered ways of living across the globe. Now, more than two years later, the effects are still felt widely. Many non-emergent... 
Via Brandpoint
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
Making its debut on 05/08/2007, smart beta exchange traded fund First Trust Large Cap Core AlphaDEX ETF (ETF:FEX) provides investors broad exposure to the Style Box - Large Cap Blend category of the... 
Via Benzinga
Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic Breast Cancer
 
Via Benzinga
Everest Medicines Descends To New Depths On String Of Bad News
Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue... 
Via Benzinga
Gilead's Lenacapavir Scores European Approval For Pretreated HIV Patients After Manufacturing Delays
 
Via Benzinga
Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront). 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
 
Via Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
How they handle an upcoming shift in payments will be telling for their tailwind. 
Via Investor's Business Daily
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.